Amylin Obesity Combo Scores Big Weight Loss In Phase IIa Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
Subjects taking pramlintide/metreleptin lost a significant 12.7 percent of body weight compared with 8.4 percent for subjects on pramlintide alone.
You may also be interested in...
In Defense Of “Me-Too” Drugs: Is Primary Care Losing Out To Rare Disease R&D?
Regulatory and financial incentives have sparked major investment in orphan drug development. One-third of the new molecular entities and novel biologics approved by FDA in the past five years have been orphan drugs. But now some stakeholders are questioning whether the focus on orphans is orphaning another market: primary care conditions that are still not adequately treated. Are incentives needed?
Amylin Halts Development Of Symlin With Approved Appetite Suppressants
The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.
Amylin Halts Development Of Symlin With Approved Appetite Suppressants
The 2009 filing timeline for once-weekly exenatide could be hastened if FDA does not require bioequivalence data, firm says.